Triparanol

Triparanol (INN, BAN) (brand and developmental code names MER/29, as well as many other brand names), patented in 1959 and introduced in the United States in 1960, was the first synthetic cholesterol-lowering drug. It was withdrawn in 1962 due to severe adverse effects such as nausea and vomiting, vision loss due to irreversible cataracts, alopecia, skin disorders (e.g., dryness, itching, peeling, and "fish-scale" texture), and accelerated atherosclerosis and is now considered to be obsolete. The drug acts by inhibiting 24-dehydrocholesterol reductase, which catalyzes the final step of cholesterol biosynthesis, the conversion of desmosterol into cholesterol. This results in tissue accumulation of desmosterol, which in turn is responsible for the side effects of triparanol. Unlike statins, triparanol does not inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, and in contrast to triparanol, statins can significantly lower cholesterol levels without resulting in accumulation of intermediates like desmosterol. The developmental code name of triparanol, MER/29, became so well-known that it became the registered trade name of the drug.

Estrogen is known to lower cholesterol levels, but produces side effects like gynecomastia and decreased libido in men. It was hoped that a drug could be developed that lacked overt estrogenic effects but still lowered cholesterol levels. Triparanol is a triphenylethanol and was derived from chlorotrianisene (TACE), a non-steroidal triphenylethylene estrogen, and the non-steroidal triphenylethanol antiestrogen ethamoxytriphetol (MER-25) is a derivative of triparanol. The selective estrogen receptor modulator clomifene is also structurally related to triparanol. The developers of triparanol jokingly referred to it as a "non-estrogenic estrogen".